Ei­sai’s can­cer drug Halaven at the cen­ter of $2B pact with Bliss­Bio, like its Bris­tol My­ers ADC deal

Ei­sai plans to pay up to $2 bil­lion to de­vel­op an an­ti­body-drug con­ju­gate with Chi­nese biotech Bliss Bio­phar­ma­ceu­ti­cal, and the Japan­ese bio­phar­ma could gain ex-Greater Chi­na rights to the ADC, which in­cludes its can­cer med Halaven.

The com­pa­nies said Mon­day that Ei­sai will pay an undis­closed up­front amount to co-de­vel­op BB-1701 through an op­tion pe­ri­od, at which point the duo can form a strate­gic col­lab­o­ra­tion. The ADC us­es Halaven as a pay­load, with the goal of treat­ing breast, lung and oth­er sol­id tu­mors ex­press­ing HER2.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER